TSX:ONC - Post Discussion
Post by
Noteable on Nov 17, 2024 4:02pm
HDAC inhibitor resistant cells vulnerable to pelareorep
In a 2020 paper Islam et al. reported that their investigation revealed that HDAC inhibitor-resistant cells displayed enhanced vulnerability to reovirus replication and cell death in both in vitro and in vivo models compared with their parental counterparts.
https://pubmed.ncbi.nlm.nih.gov/33108458/ On November 15, 2024 a new study led by researchers at Johns Hopkins Kimmel Cancer Center and Oregon Health & Science University found that a combination of two drugs could turn pancreatic tumors, which are typically resistant to immunotherapy, into more immune-responsive cancers, and provided further evidence of another avenue of pelareorep's mechanism of action in PDAC.
A Phase II clinical trial, led by Nilofer Azad, MD, an associate professor of oncology at Johns Hopkins University School of Medicine, and Marina Baretti, MD, an assistant professor of oncology at Johns Hopkins University School of Medicine, tested a combination of nivolumab, an immunotherapy, and entinostat, an epigenetic drug that modifies gene expression by inhibiting histone deacetylase (HDAC). This combination was given to 27 patients with advanced PDA who had already been treated with chemotherapy. The trial showed promising results in a subset of patients, with three participants experiencing significant tumor shrinkage and a period without disease progression lasting a median of 10.2 months. “This was the first time that we combined these drugs in patients with PDA, and we were reassured by the safety profile,” said Baretti. “We saw a profound and durable response in a subset of patients. Now we need to understand better how we can expand this benefit for a larger patient population.”
https://www.insideprecisionmedicine.com/topics/oncology/drug-combination-boosts-immune-response-in-resistant-pancreatic-cancers/
Be the first to comment on this post